ES2149340T3 - Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso. - Google Patents

Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.

Info

Publication number
ES2149340T3
ES2149340T3 ES95903265T ES95903265T ES2149340T3 ES 2149340 T3 ES2149340 T3 ES 2149340T3 ES 95903265 T ES95903265 T ES 95903265T ES 95903265 T ES95903265 T ES 95903265T ES 2149340 T3 ES2149340 T3 ES 2149340T3
Authority
ES
Spain
Prior art keywords
pct
disaccharides
glucosamine
disacarids
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903265T
Other languages
English (en)
Inventor
John Gwynfor Davies
Jacques Bauer
Pierre Hirt
Adrian Schulthess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OM Pharma SA
DEUTSCHE OM ARZNEIMITTEL GmbH
Original Assignee
OM Pharma SA
DEUTSCHE OM ARZNEIMITTEL GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OM Pharma SA, DEUTSCHE OM ARZNEIMITTEL GmbH filed Critical OM Pharma SA
Application granted granted Critical
Publication of ES2149340T3 publication Critical patent/ES2149340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A DISACARIDOS DE GLUCOSAMINA BETA(1-6) DE LA FORMULA GENERAL (I) Y A UN METODO PARA PREPARAR ESTOS DISACARIDOS, QUE INCLUYE LOS PASOS DE (I) PROPORCIONAR UN MATERIAL INICIADOR QUE INCLUYE UNA MITAD A LIPIDA DE MICROORGANISMOS QUE CONTIENEN LIPOPOLISACARIDOS; Y (II) SOMETER DICHO MATERIAL A UN TRATAMIENTO ALCALINO DE MANERA QUE LA MITAD A LIPIDA SEA O-DESACILADA EN LA POSICION -3 Y EN LA POSICION-3'', Y COMPOSICIONES FARMACEUTICAS QUE INCLUYEN COMO INGREDIENTE ACTIVO ESTOS DISACARIDOS Y LOS DISACARIDOS PARA SU USO COMO AGENTES INMUNOMODULADORES, AGENTES ANTITUMORALES Y COMPONENTES DE VACUNAS.
ES95903265T 1993-11-17 1994-11-17 Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso. Expired - Lifetime ES2149340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203223 1993-11-17
PCT/EP1994/003852 WO1995014026A1 (en) 1993-11-17 1994-11-17 Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use

Publications (1)

Publication Number Publication Date
ES2149340T3 true ES2149340T3 (es) 2000-11-01

Family

ID=8214175

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903265T Expired - Lifetime ES2149340T3 (es) 1993-11-17 1994-11-17 Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.

Country Status (22)

Country Link
US (1) US6005099A (es)
EP (1) EP0729473B1 (es)
JP (1) JP3967769B2 (es)
KR (1) KR100355470B1 (es)
CN (1) CN1055093C (es)
AT (1) ATE195740T1 (es)
AU (1) AU700485B2 (es)
BR (1) BR9408071A (es)
CA (1) CA2175375C (es)
CZ (1) CZ290331B6 (es)
DE (1) DE69425671T2 (es)
DK (1) DK0729473T3 (es)
ES (1) ES2149340T3 (es)
GR (1) GR3034872T3 (es)
HU (1) HU219810B (es)
PL (1) PL181241B1 (es)
PT (1) PT729473E (es)
RO (1) RO115731B1 (es)
RU (1) RU2154068C2 (es)
SI (1) SI0729473T1 (es)
SK (1) SK281944B6 (es)
WO (1) WO1995014026A1 (es)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6372457B1 (en) * 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
US7157092B1 (en) * 1998-06-30 2007-01-02 Om Pharma Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
CA2362246A1 (en) 1999-02-10 2001-08-10 Sankyo Company, Limited Ether type lipid a1-carboxylic acid analogues
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
AU780577B2 (en) * 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
AU1581400A (en) * 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
KR100898844B1 (ko) * 1999-12-22 2009-05-21 옴 파르마 작용기화된 보조 아암을 가진 아실 슈도디펩티드
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
DE10111682B4 (de) * 2001-03-09 2004-03-25 Aventis Pharma Deutschland Gmbh Caloporosid-Derivate, Verfahren zu deren Herstellung und deren Verwendung
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
RU2288723C2 (ru) * 2002-02-04 2006-12-10 Корикса Корпорейшн Профилактическое и терапевтическое лечение инфекционных и других заболеваний с помощью иммуноэффективных соединений
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
BR0312656A (pt) * 2002-07-08 2005-06-07 Corixa Corp Processos para a produção de imunoefetores fosfato glicosaminìdeo de aminoalquila e dissacarìdeos e seus intermediários
EP2277533B1 (en) 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2006095270A1 (en) * 2005-03-10 2006-09-14 Om Pharma Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
MX2007002271A (es) * 2004-07-23 2007-06-15 Om Pharma Terapia anticancer combinada y composiciones farmaceuticas para la misma.
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN105727276A (zh) 2006-07-17 2016-07-06 葛兰素史密丝克莱恩生物有限公司 流感疫苗
CA2657353A1 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2433648A3 (en) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
PL2114421T3 (pl) 2007-03-05 2018-07-31 Om Pharma Ekstrakt bakteryjny do stosowania względem zaburzeń oddechowych i sposób jego wytwarzania
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
US10040825B2 (en) 2007-12-19 2018-08-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
US20120164178A1 (en) 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
AU2009293595A1 (en) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
MX338898B (es) 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
EP2442827B1 (en) * 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
DK2445526T3 (en) 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2774555A1 (en) 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Immunodiffusion assay for influenza virus
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011116262A2 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
AR083454A1 (es) 2010-10-15 2013-02-27 Glaxosmithkline Biolog Sa Antigeno de citomegalovirus
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
SG194733A1 (en) 2011-05-17 2013-12-30 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
BR112014006175B1 (pt) 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9518078B2 (en) * 2012-04-12 2016-12-13 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA031879B1 (ru) * 2013-06-04 2019-03-29 Пётр Геннадиевич Апарин Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US11052142B2 (en) * 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CA2920934C (en) 2013-08-30 2022-12-06 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016140702A1 (en) 2015-03-03 2016-09-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces Display platform from bacterial spore coat proteins
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016207730A1 (en) 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
WO2016207408A1 (en) 2015-06-26 2016-12-29 Institute For Research In Biomedicine Novel vaccines in prevention and treatment of malaria
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MA43773B1 (fr) 2016-03-14 2026-01-30 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
EP3504230A1 (en) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CN110945022B (zh) 2017-04-19 2024-04-05 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
PL3752182T3 (pl) 2018-02-12 2024-11-25 Inimmune Corporation Ligandy receptorów toll-podobnych
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
US20250082745A1 (en) 2021-12-13 2025-03-13 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
EP4713008A2 (en) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2026041647A1 (en) 2024-08-19 2026-02-26 Om Pharma Sa Small molecule targeting tlr4 overexpressing tumors and associated immunosuppressive, angiogenic and fibrotic complications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501582A (nl) * 1985-02-12 1986-09-01 Philips Nv Videosignaalverwerkingsschakeling voor de verwerking van een geinterlinieerd videosignaal.
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SU1652319A1 (ru) * 1988-07-25 1991-05-30 Тихоокеанский институт биоорганической химии Дальневосточного научного центра АН СССР Производные хитоолигосахаридов, обладающие иммуномодулирующей и противоопухолевой активностью
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体

Also Published As

Publication number Publication date
CA2175375C (en) 2010-01-05
DK0729473T3 (da) 2000-10-30
CZ290331B6 (cs) 2002-07-17
JPH09505071A (ja) 1997-05-20
CA2175375A1 (en) 1995-05-26
HU219810B (hu) 2001-08-28
JP3967769B2 (ja) 2007-08-29
PL181241B1 (pl) 2001-06-29
PL314494A1 (en) 1996-09-16
RO115731B1 (ro) 2000-05-30
AU1219495A (en) 1995-06-06
DE69425671T2 (de) 2001-04-19
SK61396A3 (en) 1996-11-06
CN1137799A (zh) 1996-12-11
SK281944B6 (sk) 2001-09-11
US6005099A (en) 1999-12-21
AU700485B2 (en) 1999-01-07
KR100355470B1 (ko) 2003-02-17
SI0729473T1 (en) 2001-02-28
EP0729473A1 (en) 1996-09-04
WO1995014026A1 (en) 1995-05-26
ATE195740T1 (de) 2000-09-15
BR9408071A (pt) 1996-12-24
EP0729473B1 (en) 2000-08-23
HUT74738A (en) 1997-02-28
CZ141896A3 (en) 1996-10-16
PT729473E (pt) 2001-02-28
CN1055093C (zh) 2000-08-02
RU2154068C2 (ru) 2000-08-10
DE69425671D1 (de) 2000-09-28
HU9601312D0 (en) 1996-07-29
GR3034872T3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
BR9408071A (pt) Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
BR9408377A (pt) Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
TR199901578T2 (xx) Klaritromisin form 0 kristali
CA2188043A1 (en) 7,11 disubstituted camptothecin derivatives, formulations containing such derivatives and their use
BR9506828A (pt) Composição contendo nebivolol micronizado
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
NZ308293A (en) Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids
YU62999A (sh) C-4"-supstituisani derivati makrolida
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
NZ307055A (en) Immunostimulating-wound healing compositions and methods for preparing and using same
HUT60713A (en) Process for producing pharmaceutical compositions suitable for treating hiv infections and for producing their active ingredients
DK81885A (da) Pyrido-benzothiazinderivater, fremgangsmaade til fremstilling deraf ogfarmaceutisk praeparat indeholdende mindst et saadant derivat
MX9201295A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contienen.
ATE148990T1 (de) Ebastin oder ebastin-analoga enthaltende arzneimittel
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
MX9300707A (es) Composiciones liposomaticas topicas que comprenden piroxicam y procedimiento para su preparacion.
PT99911A (pt) Processo para a preparacao de 11beta-aril-4-estrenos modificados em posicao 6,7 e de composicoes farmaceuticas que os contem
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
IE43125L (en) Aminoglycoside derivative
ES2087178T3 (es) Disulfato de ws7622a, procedimiento para su preparacion y su uso.
ES2170377T3 (es) Composicion que contiene quitosana.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 729473

Country of ref document: ES